XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value of Financial Instruments - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended
Feb. 20, 2020
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Fair Value, Option, Quantitative Disclosures [Line Items]        
Revenues   $ 369,975 $ 300,784  
Contingent consideration liabilities   2,700   $ 2,700
Convertible Debt        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Long-term debt   575,000    
Debt fair value adjustment   636,000    
Progenics        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Aggregate cash payments percentage 40.00%      
Potential payments, high   85,000    
Progenics | Cash Payments 2022        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Contingent consideration liabilities $ 100,000      
Progenics | Cash Payments 2023        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Contingent consideration liabilities $ 150,000      
Progenics | Net Sales Targets for Azedra        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Potential payments, high   70,000    
Progenics | 1095 commercialization milestone        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Potential payments, high   5,000    
Progenics | 1404 Commercialization Milestone        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Potential payments, high   $ 10,000